NexgenRx Inc.
TSX VENTURE : NXG

NexgenRx Inc.

May 22, 2009 14:18 ET

NexgenRx Announces 2009 First Quarter Results

TORONTO, ONTARIO--(Marketwire - May 22, 2009) - NEXGENRX INC. (TSX VENTURE:NXG) ("NexgenRx" or the "Corporation") is pleased to announce its 2009 first quarter results.

Revenue from transaction fees for the three months ended March 31, 2009, of $780,000, represented an increase of $549,000 over the same period in the prior year.

The net loss for the three months ended March 31, 2009 was $458,000 ($0.01 per common share), compared with a loss of $1,011,000 ($0.03 per common share) for the same period in the prior year.

Looking forward, NexgenRx continues to build relationships with established organizations that are leaders in third party administration and analytical data reporting. By aligning with these organizations, NexgenRx brings added-value to current and new customers.

The Corporation's Interim Financial Statements and Notes, Management's Discussion and Analysis, and all additional required financial disclosure in respect of the period ended March 31, 2009, are available at www.sedar.com.

About NexgenRx

NexgenRx is a growing health benefits management company engaged in the design, management and administration of health benefit plans offered by employers and other plan sponsors for the benefit of their employees and plan members. More information on NexgenRx can be found at www.nexgenrx.com.

Caution Regarding Forward-Looking Statements - This news release contains certain forward-looking statements, including statements regarding the business and anticipated financial performance of the Corporation. These statements are subject to a number of risks and uncertainties. Actual results may differ materially from results contemplated by the forward-looking statements. When relying on forward-looking statements to make decisions, investors and others should carefully consider the foregoing factors and other uncertainties and should not place undue reliance on such forward-looking statements.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Contact Information

  • NexgenRx Inc.
    Ronald C. Loucks
    President and CEO
    (416) 695-3393 x 801
    (647) 722-2920 (FAX)
    or
    NexgenRx Inc.
    Jeff Dawley
    Chief Financial Officer
    (416) 695-3393 x 806
    (647) 722-2921 (FAX)
    Website: www.nexgenrx.com